Serological Tests for Disease Diagnosis: A Complete Guide to Antibody Detection

A 28-year-old woman presents to a health post with two weeks of fever and joint pain. A rapid diagnostic test for dengue IgM/IgG is performed and returns positive. The clinician diagnoses dengue fever and starts supportive treatment.

Three weeks later, she returns — still unwell. A repeat serology now shows a four-fold rise in Widal test titer. She had typhoid fever all along, and the dengue IgG was a remnant from an infection three years prior.

This case illustrates the most important principle in serology: antibody detection is indirect evidence of infection, not proof of current disease. Understanding how to interpret serological tests — what a positive result means, what it does not mean, when to trust it and when to repeat — is as important as knowing which test to order.

This article is the hub for all serological and immunodiagnostic content on Microbeonline. It explains the principles of antibody-based diagnosis, guides interpretation, and links to detailed articles for each specific test.

What This Hub Covers

Section	What you will learn
How antibodies are produced and detected	B cell activation, seroconversion, window period
Why antibody presence ≠ current infection	Passive transfer, vaccination, cross-reactivity
How to interpret serological results	4-fold rise, IgM vs IgG, cut-off titers
Antigen detection vs antibody detection	When to use which approach
Major serological test methods	ELISA, ICT, HAI, CFT, RIA, IFA, agglutination
Disease-specific serology	Dengue, Hepatitis B, HIV, Syphilis, Typhoid, and more

Companion article: This hub covers antibody-based diagnostic tests. For antigen-based tests — NS1 dengue antigen, malaria RDTs, pneumococcal urinary antigen, HBsAg, HIV p24, H. pylori stool antigen, Cryptococcal CSF antigen — see Antigen Detection Tests for Disease Diagnosis.

Jump to any section using the table of contents, or use the links throughout to access full detailed articles on each test method or disease.

Antibodies are glycoproteins produced by our body in response to invading organisms or toxins (antigens). When a pathogen (bacteria, virus, protozoa, or helminth) enters our body and somehow manages to reach our bloodstream, antigen-presenting cells (such as macrophages, dendritic cells, or B cells) circulating in the bloodstream capture these pathogens and either destroy them or present them to appropriate T cells.

Receptors present on naïve B cells recognize the surface proteins of the pathogen. Antigens and other signals (such as MHC-II-peptide:TCR interaction and CD40-CD40L interaction) activate these naïve B cells. This results in the proliferation of antigen-specific cells (clonal expansion) and their differentiation into effector cells that actively secrete antibodies.

Figure: B Cell Activation and formation of Antibodies(Image source: Abbas-Cellular and Molecular Immunology)

All these signals lead to activation of naïve B cells and convert them into antibody-producing cells (plasma cells). After the plasma cells start production of antibodies, the concentration of antibodies in the blood begins to rise slowly, as the initially formed antibodies are consumed in antigen capture (formation of Ag-Ab complex) and neutralization.  As time passes and the disease progresses, the concentration of antigen in the bloodstream declines to a negligible level, while the concentration of antibodies increases to a detectable level. Seroconversion is the period between infection and the appearance of detectable antibodies in the serum; this duration varies by infection.

Presence of Antibodies in Blood ≠ Infection

In any systemic infection, antigen (Ag) always appears in the blood before antibodies do. For this reason, antigen detection tests or culture (when available) are used for initial diagnosis, and serological tests are used later.

If the pathogen does not reach the bloodstream or fails to mount sufficient humoral response, antibody detection tests may not be applicable to detect such infections. For example, antibody detection tests are not used to detect local or superficial skin infections (e.g. dermatophytoses), cholera (a toxin-mediated illness with no bloodstream invasion), giardiasis, etc.

The presence of antibodies against a particular infection (or pathogen of interest) should not be interpreted as evidence of active infection at that time, because antibodies may be present in the serum of individuals due to any of the following conditions:

1. Vaccination
2. Previous infection or sub-clinical infection (which is already subsided)
3. Infection with another organism having antigenic similarity with the pathogen of interest
4. Passively acquired from mother: If the person is a newborn, they might have acquired those antibodies from their mother through the placenta or breast milk. (All newborns of mothers who are antibody-positive for a particular disease/pathogen will have passively transferred maternal IgG. In such cases, titer can be high but may not indicate infection in the baby.

Following approaches should be used during interpretation of the serological tests

1. A four-fold rise in antibody titer between acute- and convalescent-phase samples.
2. Detection of IgM antibody against the pathogen of interest (indicates recent infection).
3. Antibody titer should exceed the prevailing cut-off titer in the general population.

The choice of the test methods for a particular pathogen of interest differs based on the nature of the organism, cost of the test procedure and facility available in the diagnostic laboratories.

Understanding the Window Period and Seroconversion

The window period is the time between infection and the appearance of detectable antibodies in serum. During this period, a patient may be infectious but serologically negative — a critically important concept for both clinical diagnosis and blood bank screening.

Window periods vary significantly between infections:

Infection	Window period (approximate)	First antibody detectable
HIV	18–45 days (3rd generation ELISA); 15–20 days (4th generation Ag/Ab combo)	IgM, then IgG
Hepatitis B	6 weeks – 6 months	Anti-HBc IgM
Hepatitis C	8–11 weeks (antibody); 1–2 weeks (RNA PCR)	Anti-HCV IgG
Dengue	3–5 days (IgM); 14+ days (IgG)	IgM earlier in primary infection
EBV (mono)	4–7 days after symptoms begin	Heterophile antibodies
Syphilis	3–6 weeks after exposure	IgM (treponemal)

Clinical implication: A negative serological test during the window period does not rule out infection. For HIV, a confirmed negative result requires testing 6 weeks after the last potential exposure (using 4th-generation tests) or 3 months (with older tests). For blood bank screening, NAT (nucleic acid testing) is used specifically because it detects the virus before antibodies appear.

Antigen Detection vs Antibody Detection: When to Use Which

In any infection, antigen (the pathogen or its components) appears in the blood before antibodies. This has direct implications for test selection:

Approach	What is detected	Best for	Limitation
Antigen detection	The pathogen or its proteins directly	Early infection (before seroconversion); immunocompromised patients who may not mount antibody response	Antigen cleared quickly; may miss late-stage disease
Antibody detection (IgM)	Recent/acute infection	Diagnosis 5–14 days after onset; distinguishes recent from past infection	Window period — negative early; may cross-react
Antibody detection (IgG)	Past infection or immunity	Seroprevalence studies; vaccination response; paired samples (4-fold rise confirms acute infection)	Persists for life — positive does not mean current infection
Paired serology	Rising antibody titer	Gold standard for many viral infections	Requires two samples 2–4 weeks apart; delays diagnosis
Culture / molecular (PCR)	The organism directly	Definitive diagnosis; drug sensitivity testing	Slow (culture); expensive (PCR); not available everywhere

The clinical rule: When a patient is acutely ill, start with antigen detection or culture if available. When culture is negative or unavailable, or when diagnosis is retrospective, use serology. When confirming immunity (e.g., post-vaccination HBsAb), IgG is appropriate.

Serological Test Methods (Overview with Links)

Choice of method depends on the pathogen, the cost of the test, and what's available in the lab — a district hospital and a tertiary referral center won't reach for the same test. The following table maps every major serological test method to its principle, clinical applications, and detailed article on this site:

Method	Principle	Key applications	Detailed article
ELISA (Enzyme-Linked Immunosorbent Assay)	Antigen or antibody bound to solid phase; enzyme-linked conjugate; colour reaction	HIV, HBV, HCV, dengue, toxoplasma; most versatile serological platform	ELISA
Immunochromatography (ICT/RDT)	Lateral flow; antibody-labelled coloured particles migrate across membrane	Rapid diagnosis: malaria, dengue, HIV, typhoid, COVID-19, pregnancy tests	Immunochromatography
Haemagglutination Inhibition (HAI)	Antibodies inhibit virus-mediated red cell agglutination	Influenza, rubella, mumps serology	HAI test
Widal Test (tube/slide agglutination)	Patient antibodies agglutinate killed Salmonella antigens	Typhoid fever serology	Widal test
TPHA	Patient antibodies agglutinate T. pallidum-coated particles	Confirmatory syphilis test	TPHA
RPR (Rapid Plasma Reagin)	Non-treponemal; antibodies react with cardiolipin antigen; carbon particle flocculation	Syphilis screening; treatment monitoring	RPR
FTA-ABS	Indirect fluorescent antibody; patient antibodies react with T. pallidum	Confirmatory syphilis; most sensitive treponemal test	FTA-ABS
VDRL	Non-treponemal flocculation; cardiolipin antigen	Syphilis screening; CSF VDRL for neurosyphilis	VDRL
ASO Titer	Latex agglutination; antibodies to streptolysin O	Post-streptococcal disease (rheumatic fever, GN)	ASO titer
Monospot Test	Heterophile antibody agglutination of horse/ox RBCs	Infectious mononucleosis (EBV)	Monospot test
Complement Fixation Test (CFT)	Antigen-antibody complex fixes complement; indicator system (sensitised RBCs)	Mycoplasma, rickettsia, viral serology	CFT
Radioimmunoassay (RIA)	Radiolabelled antigen competes with patient antigen for antibody binding	Hormone levels; hepatitis markers; high sensitivity applications	RIA
Direct Fluorescent Antibody (DFA)	Fluorescent-labelled antibody applied directly to specimen	Rapid detection of organisms in tissue/smears (Legionella, Bordetella, HSV)	DFA
Indirect Fluorescent Antibody (IFA)	Patient antibody binds antigen; fluorescent anti-human IgG secondary antibody	ANA (autoimmune), IFAT for malaria/Leishmania, FTA-ABS	IFA
Immunofluorescence Assay (IFA general)	Fluorescent labelling for antigen or antibody detection	Wide range: viral, bacterial, parasitic, autoimmune	Immunofluorescence
CIE (Counterimmunoelectrophoresis)	Antigen and antibody migrate toward each other in electric field; precipitin line forms	Bacterial antigen detection in CSF (Pneumococcus, Meningococcus, Haemophilus)	CIE
Western Blot	Electrophoresis separates antigens; patient antibodies detected by band pattern	HIV confirmatory; Lyme disease confirmation	Western Blot
Hepatitis B serology interpretation	Combined antigen (HBsAg, HBeAg) and antibody (anti-HBc, anti-HBs) panel	Staging HBV infection; vaccination response; carrier identification	HBV serology

The following diseases are commonly diagnosed serologically. For each, the table provides the test name, what is detected, and the key clinical note. Click through to the detailed article for full procedure, interpretation, and troubleshooting.

Disease	Test(s) used	What is detected	Key clinical note	Article
Dengue fever	NS1 antigen RDT/ELISA (days 1–7); IgM/IgG ELISA; HAI	NS1 antigen (acute phase); Anti-dengue IgM (primary); IgG (secondary/past)	NS1 antigen detectable days 1–7, use before IgM appears; IgM detectable by day 3–5; IgG cross-reacts with other flaviviruses	Dengue virus
Malaria	RDT (HRP2, pLDH); blood film microscopy	HRP2 antigen (P. falciparum); pLDH (all species); aldolase (pan-malarial)	RDTs detect antigen directly — no antibody window period; HRP2 most sensitive for P. falciparum; pLDH distinguishes species	Malaria-Lab Diagnosis
Hepatitis B	HBsAg, HBeAg, anti-HBc, anti-HBs (panel)	Antigen (active infection) + antibody (immunity/past)	Panel interpretation distinguishes acute, chronic, carrier, immune states	HBV serology
HIV/AIDS	RDTs (Tri-Dot); ELISA; Western Blot	Anti-HIV IgG/IgM; p24 antigen (4th gen)	Window period 18–45 days; neonatal diagnosis requires PCR not serology	HIV/AIDS
Post-streptococcal disease	ASO titer	Anti-streptolysin O antibody	>200 IU/mL indicates recent S. pyogenes infection; titer remains elevated weeks after infection	ASO titer
Syphilis	RPR/VDRL (screening) + TPHA/FTA-ABS (confirmatory)	Non-treponemal (cardiolipin) + treponemal antibodies	Two-test algorithm: screen with non-treponemal; confirm with treponemal; treat based on clinical stage	RPR · TPHA · FTA-ABS
Typhoid fever	Widal test	Agglutinating antibodies against O, H, AH, BH antigens	Positive after day 10; cut-off depends on population baseline — your own research (anti-O >1:80, anti-H >1:160 for Nepal)	Widal test
Visceral leishmaniasis	rK39 RDT; IFAT	Anti-rK39 IgG	rK39 rapid test highly sensitive and specific for kala-azar in endemic areas	Leishmaniasis lab diagnosis
Hepatitis C	Anti-HCV ELISA; HCV RNA (confirmatory)	Anti-HCV IgG	Antibodies persist for life; positive serology requires RNA PCR confirmation of active infection	Hepatitis C Virus
Infectious mononucleosis	Monospot (heterophile); EBV-specific IgM/IgG	Heterophile antibodies; anti-VCA IgM/IgG	Monospot false-negative in <5 years age; VCA IgM = primary infection; IgG anti-EBNA = past infection	Monospot test
Brucellosis	Standard tube agglutination (STA); Rose Bengal Plate Test	Anti-Brucella agglutinins	Titre ≥1:160 suggestive; common cause of PUO; zoonosis in cattle-farming regions	Brucella

How to Remember

The serology timeline — three phases of every infection:

EXPOSURE
    ↓
[Window period — culture or antigen detection only]
    ↓
IgM appears (3–14 days post-onset) → ACUTE infection
    ↓
IgG rises, IgM declines → RECENT/RESOLVING infection
    ↓
IgM gone, IgG persists → PAST infection or immunity

This single timeline explains 90% of serology interpretation questions. The key variable is which immunoglobulin class is elevated and when relative to symptoms.

The two-test rule for syphilis: Screen with a non-treponemal test (RPR or VDRL; cheap, quantitative, monitors treatment). Confirm with a treponemal test (TPHA or FTA-ABS; specific, stays positive for life). Never diagnose syphilis on a non-treponemal test alone; false positives from lupus, pregnancy, and other conditions are common.

The four reasons antibodies can be positive without current infection:

1. Vaccination
2. Past resolved infection
3. Cross-reactive antigen (another organism)
4. Passive maternal antibody (neonates)

Memorise these four because they appear in every serology interpretation question and clinical scenario involving unexpected positive results.

References

1. Delforge M. L. (2011). De l’utilité ou non de la sérologie infectieuse: morceaux choisis [On the usefulness of serology testing in infectious diseases: selected topics]. Revue medicale de Bruxelles, 32(4), 285–288.
2. Feng, Z., Li, Z., Sui, B., Xu, G., & Xia, T. (2005). Serological diagnosis of infectious mononucleosis by chemiluminescent immunoassay using capsid antigen p18 of Epstein-Barr virus. Clinica chimica acta; international journal of clinical chemistry, 354(1-2), 77–82. https://doi.org/10.1016/j.cccn.2004.11.010
3. Delforge M.L. (2011). De l'utilité ou non de la sérologie infectieuse. Revue médicale de Bruxelles, 32(4), 285–288. (keep)
4. Feng Z. et al. (2005). Serological diagnosis of infectious mononucleosis. Clinica chimica acta, 354(1-2), 77–82. (keep)
5. Tille, P. M. (2017). Bailey and Scott's Diagnostic Microbiology (14th ed.). Elsevier.
6. WHO. (2003). Manual for the Laboratory Identification and Antimicrobial Susceptibility Testing of Bacterial Pathogens of Public Health Importance. Geneva: WHO.
7. Acharya T., Tiwari B.R., Pokhrel B.M. (2013). Reassessment of the Widal Test Cut-Off Titre for Diagnosis of Typhoid Fever in the Nepalese Context. JHAS, 3(1):27–30.